Home › Merck to Present New Data on ZEPATIER (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting 2016
 

Keywords :   


Merck to Present New Data on ZEPATIER (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting 2016

2016-10-03 14:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the companys chronic hepatitis C virus (HCV) clinical development programs will be presented at The Liver Meeting 2016. Fifteen scientific abstracts, including seven oral and eight poster presentations, will highlight findings from Mercks HCV clinical development programs. Language: English Contact: MerckMedia:Doris Li, 908-740-1903Ian McConnell, 908-740-1921orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the data development present

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
09.05Skin Care Composition Prevents and Treats Pollution Damage
09.05Demand, crop prospects, global geopolitics: What's ahead?
09.05Scalstrm and EZDRM partner on video content security
09.05Appvion launches EarthChem sustainable direct thermal portfolio
09.05Glatfelter Reports Financial Results
09.05Maryland Adopts PaintCare Program
09.05Society of Cosmetic Chemists Intermountain West to Host Healthy Bite Oral Care Symposium
09.05A.Celli and Akinal Tekstil Collaborate on Line Installation
More »